Tg Therapeutics (TGTX) Accumulated Expenses (2010 - 2026)

Tg Therapeutics' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $18.7 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 263.29% year-over-year to $18.7 million; the TTM figure through Mar 2026 stood at $18.7 million (up 263.29% YoY), while the FY2025 annual figure was $21.8 million, up 43.89% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $18.7 million, down from $21.8 million in the prior quarter.
• The five-year high for Accumulated Expenses was $21.8 million in Q4 2025, with the low at $1.6 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $8.3 million (2023), against an average of $9.1 million.
• The sharpest annual moves came in 2022 and 2026: Accumulated Expenses plunged 66.57% in 2022, then surged 263.29% in 2026.
• Tg Therapeutics' Accumulated Expenses stood at $8.4 million in 2022, then surged by 44.35% to $12.2 million in 2023, then climbed by 24.75% to $15.2 million in 2024, then soared by 43.89% to $21.8 million in 2025, then decreased by 14.62% to $18.7 million in 2026.
• Business Quant data shows TGTX's Accumulated Expenses at $18.7 million in Q1 2026, $21.8 million in Q4 2025, and $15.0 million in Q3 2025.